Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

BMC Nephrology

Volumn 10, Issue 1, 2009, Pages

  Barraclough, Katherine A ^a   Noble, Euan ^a   Leary, Diana ^a   Brown, Fiona ^b   Hawley, Carmel M ^a   Campbell, Scott B ^a   Isbel, Nicole M ^a   Mudge, David W ^a   Van Eps, Carolyn L ^a   Sturtevant, Joanna M ^a   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; FERROUS SULFATE; FOLIC ACID; HEMOGLOBIN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN; VITAMIN B GROUP; DRUG DERIVATIVE; ERYTHROPOIETIN; FERROUS ION; HAEMOFERRITIN; HEMOPROTEIN; IRON;

ANALYSIS OF COVARIANCE; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIALYSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; TABLET FORMULATION; TRANSFERRIN SATURATION; TREATMENT OUTCOME; ADULT; AUSTRALIA; BLOOD; CHRONIC DISEASE; DELAYED RELEASE FORMULATION; KIDNEY DISEASE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANEMIA; AUSTRALIA; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; ERYTHROPOIETIN; FERRITINS; FERROUS COMPOUNDS; HEMATINICS; HEMEPROTEINS; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; PERITONEAL DIALYSIS; TREATMENT OUTCOME;

EID: 69049085732     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-10-20     Document Type: Article

References (22)

1. Anemia of end-stage renal disease (ESRD). JW Eschbach JW Adamson, Kidney Int 1985 28 1 5 10.1038/ki.1985.109 3900528
2. Erythropoiesis in patients with renal failure undergoing chronic dialysis. JW Eschbach Jr D Funk J Adamson I Kuhn BH Scribner CA Finch, N Engl J Med 1967 276 653 658 6018456
3. Erythropoietin in chronic renal failure. F Valderrabano, Kidney Int 1996 50 1373 1391 10.1038/ki.1996.452 8887302
4. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). RL Benz MR Pressman ET Hovick DD Peterson, Am J Kidney Dis 1999 34 1089 1095 10.1016/S0272-6386(99) 70015-6 10585319
5. Strategies for iron supplementation: oral versus intravenous. IC Macdougall, Kidney Int 1999 55 Suppl 69 S61 6 10.1046/j.1523-1755.1999.055Suppl. 69061.x
6. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients [letter]. O Nyvad H Danielsen S Madsen, Lancet 1994 344 1305 1306 10.1016/S0140-6736(94)90797-8 7968018
7. Intravenous ferric saccharate as an iron supplement in dialysis patients. DS Silverberg M Blum G Peer E Kaplan A Iaina, Nephron 1996 72 413 417 10.1159/000188905 8852489
8. A prospective cross-over trial comparing intermittent intravenous and continuous oral iron supplementation in peritoneal dialysis patients. DW Johnson KA Herzig R Gissane SB Campbell CM Hawley NM Isbel, Nephrol Dial Transplant 2001 16 1879 1884 10.1093/ndt/16.9.1879 11522873
9. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. GS Markowitz GA Kahn RE Feingold M Coco RI Lynn, Clin Nephrol 1997 48 34 40 9247776
10. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. RM Schaefer L Schaefer, Erythropoiesis 1992 3 71 75
11. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. TB Drueke P Barany M Cazzola JW Eschbach P Grutzmacher JP Kaltwasser IC Macdougall MJ Pippard S Shaldon D van Wyck, Clin Nephrol 1997 48 1 8 9247771
12. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. N Muirhead J Bargman E Burgess KK Jindal A Levin L Nolin P Parfrey, Am J Kidney Dis 1995 26 S1 24 10.1016/0272-6386(95)90645-2 7645549
13. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999 14 Suppl 5 1 50 10513295
14. Biochemical and haematological targets. CA Pollock D Saltissi S Roger H Healy L Barratt G Elder L McMahon S May, The CARI Guidelines Sydney: Excerpta Medica Communications, Knight J, Chu R, Smith J, Gerard J, 1 2000 19 26
15. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. BJ Barrett SS Fenton B Ferguson P Halligan S Langlois WG Mccready N Muirhead RV Weir, J Am Soc Nephrol 1999 10 Suppl 13 S292 6 10425612
16. An intestinal receptor for heme. R Grasbeck I Kouvonen M Lundberg R Tenhunen, Scand J Haematol 1979 23 5 9 493872
17. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. L Hallberg L Ryttinger L Solvell, Acta Med Scand Suppl 1966 459 3 10 5957969
18. Clinical studies of HIP: An oral heme-iron product. PA Seligman GM Moore RB Schleicher, Nutr Res 2000 20 1279 1286 10.1016/S0271-5317(00)00215-3
19. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? L Hallberg L Hulten E Gramatkovski, Am J Clin Nutr 1997 66 347 356 9250114
20. Effects of erythropoietin therapy on iron absorption in chronic renal failure. BS Skikne N Ahluwalia B Fergusson A Chonko JD Cook, J Lab Clin Med 2000 135 452 458 10.1067/mlc.2000.106807 10850644
21. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. AR Nissenson JS Berns P Sakiewicz S Ghaddar GM Moore RB Schleicher PA Seligman, Am J Kidney Dis 2003 42 325 330 10.1016/S0272-6386(03)00658-9 12900815
22. Reduced nPCR in patients with gastrointestinal side effects due to ferrous sulfate [abstract]. S Fishbane MA Goreja JK Maesaka, J Am Soc Nephrol 1998 9 Oct 248A